Search results for " lanreotide"

showing 2 items of 2 documents

Lanreotide Therapy vs Active Surveillance in MEN1-Related Pancreatic Neuroendocrine Tumors2 Centimeters.

2019

Abstract Purpose Pancreatic neuroendocrine tumors (pNETs) are frequent in multiple endocrine neoplasia type 1 (MEN1) syndrome. They are usually not surgically treated unless larger than 1 to 2 cm or a growth rate > 0.5 cm per year. Somatostatin analogues represent one of the main therapeutic options in pNETs, but they have never been prospectively investigated in MEN1-related pNETs. The aim of this study was to prospectively evaluate the effectiveness of lanreotide in patients with MEN1-related pNETs < 2 cm. Methods MEN1 patients with 1 or more pNETs < 2 cm of maximal diameter were considered. Study design was prospective observational, comparing patients treated with l…

MaleEndocrinology Diabetes and MetabolismClinical BiochemistryNeuroendocrine tumorsLanreotideBiochemistryGastroenterologychemistry.chemical_compoundEndocrinologyactive surveillance lanreotide MEN1 pancreatic neuroendocrine tumors somatostatin analoguesProspective StudiesProspective cohort studyMultiple endocrine neoplasiasomatostatin analoguesMiddle AgedPrognosisTumor BurdenNeuroendocrine TumorsSomatostatinMEN1Disease ProgressionFemalelanreotideSomatostatinAdultmedicine.medical_specialtyAntineoplastic Agentspancreatic neuroendocrine tumorPeptides CyclicYoung AdultInternal medicinemedicineMultiple Endocrine Neoplasia Type 1HumansMEN1Watchful WaitingAgedCentimeterpancreatic neuroendocrine tumorsbusiness.industryBiochemistry (medical)active surveillancemedicine.diseasePancreatic NeoplasmsEndocrinologychemistryactive surveillance; lanreotide; MEN1; pancreatic neuroendocrine tumors; somatostatin analoguesTumor progressionCase-Control StudiesbusinessFollow-Up StudiesThe Journal of clinical endocrinology and metabolism
researchProduct

Nonconventional Doses of Somatostatin Analogs in Patients With Progressing Well-Differentiated Neuroendocrine Tumor

2020

Abstract Purpose To evaluate the antiproliferative activity and safety of nonconventional high doses of somatostatin analogs (HD-SSA) in patients with well-differentiated gastroenteropancreatic (GEP) neuroendocrine tumors (NET) with radiological disease progression according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria on a previous treatment. Methods A retrospective analysis of prospectively maintained databases from 13 Italian NET-dedicated centers was performed. Main inclusion criteria were: well-differentiated G1 or G2 GEP-NET, progressive disease on a previous treatment, and subsequent treatment with HD-SSA (either by increased administered dose [dose intensity] or…

MaleEndocrinology Diabetes and MetabolismClinical BiochemistryOctreotideNeuroendocrine tumorsLanreotideBiochemistryGastroenterologychemistry.chemical_compoundEndocrinologyhigh dose80 and overMedicineProspective StudiesProspective cohort studyhigh dose; lanreotide; NET; nonconventional doses; octreotide; somatostatin analogs; Adult; Aged; Aged 80 and over; Female; Follow-Up Studies; Hormones; Humans; Liver Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Prognosis; Prospective Studies; Retrospective Studies; Somatostatin; Cell DifferentiationAged 80 and overLiver NeoplasmsCell DifferentiationMiddle Agednonconventional dosePrognosissomatostatin analogsNeuroendocrine TumorsResponse Evaluation Criteria in Solid TumorsFemalelanreotideSomatostatinmedicine.drugAdultmedicine.medical_specialtyhigh dose; lanreotide; NET; nonconventional doses; octreotide; somatostatin analogsInternal medicinenonconventional dosesHumansAdverse effectAgedRetrospective Studiesbusiness.industryBiochemistry (medical)medicine.diseaseHormonesClinical trialNETEndocrinologychemistrybusinessProgressive diseaseoctreotideFollow-Up Studies
researchProduct